SET / TAF-I Antibody
Rabbit Polyclonal Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| WB, IHC-P, ICC |
---|---|
Primary Accession | Q01105 |
Other Accession | 6418 |
Reactivity | Human, Mouse, Rat, Monkey, Chicken, Bovine |
Host | Rabbit |
Clonality | Polyclonal |
Isotype | IgG |
Calculated MW | 33489 Da |
Dilution | ICC (1:100), IHC-P (5 µg/ml), WB (1:2000), |
Gene ID | 6418 |
---|---|
Other Names | SET, 2PP2A, HLA-DR-associated protein II, I-2PP2A, TAF-IBETA, SET nuclear oncogene, TAF-I, Template-activating factor I, I2PP2A, IGAAD, IPP2A2, PHAPII, Protein SET |
Target/Specificity | Human SET |
Reconstitution & Storage | PBS, pH 7.2, 50% glycerol. Store at -20°C. |
Precautions | SET / TAF-I Antibody is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | SET |
---|---|
Function | Multitasking protein, involved in apoptosis, transcription, nucleosome assembly and histone chaperoning. Isoform 2 anti-apoptotic activity is mediated by inhibition of the GZMA-activated DNase, NME1. In the course of cytotoxic T-lymphocyte (CTL)-induced apoptosis, GZMA cleaves SET, disrupting its binding to NME1 and releasing NME1 inhibition. Isoform 1 and isoform 2 are potent inhibitors of protein phosphatase 2A. Isoform 1 and isoform 2 inhibit EP300/CREBBP and PCAF- mediated acetylation of histones (HAT) and nucleosomes, most probably by masking the accessibility of lysines of histones to the acetylases. The predominant target for inhibition is histone H4. HAT inhibition leads to silencing of HAT-dependent transcription and prevents active demethylation of DNA. Both isoforms stimulate DNA replication of the adenovirus genome complexed with viral core proteins; however, isoform 2 specific activity is higher. |
Cellular Location | Cytoplasm, cytosol. Endoplasmic reticulum. Nucleus, nucleoplasm. Note=In the cytoplasm, found both in the cytosol and associated with the endoplasmic reticulum. The SET complex is associated with the endoplasmic reticulum. Following CTL attack and cleavage by GZMA, moves rapidly to the nucleus, where it is found in the nucleoplasm, avoiding the nucleolus. Similar translocation to the nucleus is also observed for lymphocyte-activated killer cells after the addition of calcium |
Tissue Location | Widely expressed. Low levels in quiescent cells during serum starvation, contact inhibition or differentiation. Highly expressed in Wilms' tumor |
Volume | 500 µl |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Multitasking protein, involved in apoptosis, transcription, nucleosome assembly and histone chaperoning. Isoform 2 anti-apoptotic activity is mediated by inhibition of the GZMA-activated DNase, NME1. In the course of cytotoxic T- lymphocyte (CTL)-induced apoptosis, GZMA cleaves SET, disrupting its binding to NME1 and releasing NME1 inhibition. Isoform 1 and isoform 2 are potent inhibitors of protein phosphatase 2A. Isoform 1 and isoform 2 inhibit EP300/CREBBP and PCAF-mediated acetylation of histones (HAT) and nucleosomes, most probably by masking the accessibility of lysines of histones to the acetylases. The predominant target for inhibition is histone H4. HAT inhibition leads to silencing of HAT-dependent transcription and prevents active demethylation of DNA. Both isoforms stimulate DNA replication of the adenovirus genome complexed with viral core proteins; however, isoform 2 specific activity is higher.
References
von Lindern M.,et al.Mol. Cell. Biol. 12:3346-3355(1992).
Vaesen M.,et al.Biol. Chem. Hoppe-Seyler 375:113-126(1994).
Nagata K.,et al.Proc. Natl. Acad. Sci. U.S.A. 92:4279-4283(1995).
Li M.,et al.J. Biol. Chem. 271:11059-11062(1996).
Tsujio I.,et al.FEBS Lett. 579:363-372(2005).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.